About this trial
De Quervain disease is characterized by an adductor pollicis longus and extensor pollicis brevis tendons inflammation as thys pass beneath the extensor retinaculum at the radial styloid. This pathology is recognized as a musculoskeletal disorder of the upper limb triggering functional deficits resulting to possible modifications in the professional activity, sources of absenteeism, thus constituting an economic cost for society. At the etiological level, this pathology also affects young mothers (it's called "mother's wrist" or mommy thumb"), mobile phone users ("textonite", "Blackberryte") or video game players ("Nintendoite").
Currently, the treatment is mainly conservative by splint and anti-inflammatory gel and/or corticosteroid infiltration. Howewer, these therapies have undesirable effects. The interest of this study is therefore to propose another therapy based on aromatherapy gel.
Eligibility criteria
Qualifiers
Male or female patient aged 18 to 75,
Patient with unilateral De Quervain's tenosynovitis,
Patient cared in the Hand Surgery Department, SOS Mains Emergency Department or Rheumatology Department of Strasbourg University Hospitals,
Patient informed of the results of the prior medical examination,
Disqualifiers
Pregnant or breastfeeding patient,
Patient allergic to a component of the gel with essential oils, Dicloflenac®, NSAIDs, or one of the excipients
Patient treated with oral non-steroidal anti-inflammatory drugs
Patient with ongoing treatment with another ointment at the treatment application site (radial edge of the wrist)
Trial design
Treatments tested in this trial
- Diclofenac gel
- Aromatherapy gel